Gilead Expands oncology portfolio with $5bn Tubulis deal
Listed American biopharmaceutical company Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a privately held German biotechnology company, for a total potential consideration of $5bn. Under the terms of the deal, Gilead will provide an upfront cash payment of $3.15bn, with an additional $1.85bn tied to future contingent milestones. The transaction is expected to close in the…
Lone Star Funds’ $3bn deal for Lonza’s CHI division
Listed Swiss life sciences company Lonza Group has reached a definitive agreement to sell a sixty percent stake in its Capsules and Health Ingredients (CHI) division to private equity firm Lone Star Funds. The transaction values the unit at an enterprise value of 2.3bn Swiss francs, or approximately $3bn, representing an 8.5x enterprise value to EBITDA multiple on 2025 results.…
Gimv discontinuing new investments in life sciences platform
European investment firm Gimv announced a significant strategic pivot on Monday, January 26, declaring it will discontinue all new investments in its life sciences platform. This decision marks a shift in focus toward four core investment pillars: consumer, healthcare, smart industries, and sustainable cities, where the firm identifies significant growth opportunities linked to the digital transition. For healthcare operators and investors, this move signals a…